DEL AM 1 tm2322367d4_delam.htm DEL AM

AEON BIOPHARMA, INC.

5 PARK PLAZA, SUITE 1750

IRVINE, CA 92614

August 22, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Re:	Delaying Amendment for AEON Biopharma, Inc.

Registration Statement on Form S-1 (File No. 333-274094)

Ladies and Gentlemen:

Reference is made to the Registration Statement on Form S-1 (File No. 333-274094) filed with the Securities and Exchange Commission (the “Commission”) by AEON Biopharma, Inc. on August 18, 2023 (the “Registration Statement”). Pursuant to Rule 473(c) of the Securities Act of 1933, as amended (the “Act”), the following delaying amendment, prescribed by Rule 473(a) of the Act, is hereby incorporated into the facing page of the Registration Statement:

“The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.”

No fees are required in connection with this filing. If you have any questions or comments in connection with this delaying amendment, please contact our legal counsel Drew Capurro, Latham & Watkins LLP, at (714) 755-8008.

Sincerely,

AEON Biopharma, Inc.

By:	/s/ Alex Wilson
Name: Alex Wilson
Title: Chief Legal Officer & Corporate Secretary

cc: Drew Capurro, Latham & Watkins LLP

B. Shayne Kennedy, Latham & Watkins LLP

SEC Form DEL AM filed by Priveterra Acquisition Corp.